Show simple item record

dc.contributor.authorMarcon, Alessandro
dc.contributor.authorMarchetti, Pierpaolo
dc.contributor.authorAntó, Josep M
dc.contributor.authorCazzoletti, Lucia
dc.contributor.authorCerveri, Isa
dc.contributor.authorCorsico, Angelo
dc.contributor.authorFerreira, Diogenes Seraphim
dc.contributor.authorGarcia-Aymerich, Judith
dc.contributor.authorGislason, David
dc.contributor.authorHeinrich, Joachim
dc.contributor.authorJõgi, Rain
dc.contributor.authorJohannessen, Ane
dc.contributor.authorLeynaert, Bénédicte
dc.contributor.authorMalinovschi, Andrei
dc.contributor.authorPin, Isabelle
dc.contributor.authorProbst-Hensch, Nicole
dc.contributor.authorWeyler, Joost
dc.contributor.authorJanson, Christer
dc.contributor.authorJarvis, Deborah
dc.contributor.authorAccordini, Simone
dc.date.accessioned2020-04-29T12:16:07Z
dc.date.available2020-04-29T12:16:07Z
dc.date.issued2019-11-05
dc.date.submitted2020-04
dc.identifier.citationMarcon A, Marchetti P, Antó JM, et al. Atopy Modifies the Association Between Inhaled Corticosteroid Use and Lung Function Decline in Patients with Asthma. J Allergy Clin Immunol Pract. 2020;8(3):980–988.e10. doi:10.1016/j.jaip.2019.10.023en_US
dc.identifier.pmid31704441
dc.identifier.doi10.1016/j.jaip.2019.10.023
dc.identifier.urihttp://hdl.handle.net/2336/621366
dc.descriptionTo access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked Downloaden_US
dc.description.abstractBackground: Inhaled corticosteroids (ICSs) are the mainstay of asthma treatment, but response to medication is variable. Patients with allergic inflammation generally show a better short-term response to ICSs; however, studies on predictors of long-term response are few. Objective: To assess whether allergic sensitization can modify the association between ICS use and lung function decline over 20 years in adult asthma. Methods: We used data from the 3 clinical examinations of the European Community Respiratory Health Survey. We measured ICS use (no use, and use for <1.3, 1.3-8, and >8 years) and FEV1 decline among subjects with asthma over the 2 periods between consecutive examinations. We conducted a cohort study combining data of the 2 periods (906 observations from 745 subjects) to assess whether the association between ICS use and FEV1 decline was modified by allergic sensitization (IgE > 0.35 kU/L for any of house-dust mite, timothy grass, cat, or Cladosporium). Results: FEV1 decline was similar for non-ICS users, as well as ICS users for less than 1.3 years, with and without allergic sensitization. However, among subjects on ICSs for a longer period, sensitization was associated with an attenuated decline (Pinteraction = .006): in the group treated for more than 8 years, FEV1 decline was on average 27 mL/y (95% CIBonferroni-adjusted, 11-42) lower for subjects with sensitization compared with nonsensitized subjects. Conclusions: Our study suggests that biomarkers of atopy can predict a more favorable long-term response to ICSs. Randomized controlled studies are needed to confirm these findings.en_US
dc.description.sponsorshipEuropean Union's Horizon 2020 Research and Innovation programmeen_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.urlhttps://www.sciencedirect.com/science/article/pii/S2213219819309146?via%3Dihuben_US
dc.rightsCopyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.
dc.subjectAllergic sensitizationen_US
dc.subjectAsthmaen_US
dc.subjectAtopyen_US
dc.subjectCohort studyen_US
dc.subjectEpidemiologyen_US
dc.subjectIgEen_US
dc.subjectInhaled corticosteroidsen_US
dc.subjectLung function declineen_US
dc.subjectPrecision medicineen_US
dc.subjectResponse to corticosteroidsen_US
dc.subjectSteralyfen_US
dc.subjectAstmien_US
dc.subjectLunguen_US
dc.subject.meshHypersensitivityen_US
dc.titleAtopy Modifies the Association Between Inhaled Corticosteroid Use and Lung Function Decline in Patients with Asthma.en_US
dc.typeArticleen_US
dc.identifier.eissn2213-2201
dc.contributor.department1Unit of Epidemiology and Medical Statistics, Department of Diagnostics and Public Health, University of Verona, Verona, Italy. Electronic address: alessandro.marcon@univr.it. 2Unit of Epidemiology and Medical Statistics, Department of Diagnostics and Public Health, University of Verona, Verona, Italy. 3Institute for Global Health (ISGlobal), Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain. 4Division of Respiratory Diseases, IRCCS Policlinico San Matteo Foundation, Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy. 5School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia; Alergia e Imunologia, Complexo Hospital de Clinicas, Universidade Federal do Parana, Curitiba, Brazil. 6Department of Allergy, Respiratory Medicine and Sleep, Landspitali University Hospital, Reykjavik, Iceland. 7Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, University Hospital of Ludwig, Maximilians University, Munich, Germany; Comprehensive Pneumology Centre Munich, German Centre for Lung Research, Munich, Germany. 8Department of Pneumology, University of Tartu, Tartu, Estonia. 9Centre for International Health, Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway. 10Inserm-U1168, VIMA (Aging and Chronic Diseases. Epidemiological and Public Health Approaches), Villejuif, France; UMR-S 1168, UVSQ, Univ Versailles St-Quentin-en-Yvelines, St-Quentin-en-Yvelines, France. 11Department of Medical Sciences: Clinical Physiology, Uppsala University, Uppsala, Sweden. 12Pediatrics, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France; INSERM, Institut for Advanced Biosciences, Grenoble, France; Université Grenoble Alpes, Grenoble, France. 13Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel, Switzerland. 14Epidemiology and Social Medicine, StatUA Statistics Center, University of Antwerp, Antwerp, Belgium. 15Department of Medical Sciences: Respiratory, Allergy and Sleep research, Uppsala University, Uppsala, Sweden. 16National Heart and Lung Institute, Imperial College London, London, United Kingdom; MRC-PHE Centre for Environment and Health, Imperial College London, London, United Kingdom.en_US
dc.identifier.journalThe journal of allergy and clinical immunology. In practiceen_US
dc.rights.accessOpen Access - Opinn aðganguren_US
dc.departmentcodePAD12
dc.source.journaltitleThe journal of allergy and clinical immunology. In practice
dc.source.volume8
dc.source.issue3
dc.source.beginpage980
dc.source.endpage988.e10
refterms.dateFOA2020-04-29T12:16:07Z
dc.source.countryUnited Kingdom
dc.source.countryUnited States


Files in this item

Thumbnail
Name:
Publisher version
Thumbnail
Name:
atopy.pdf
Size:
1.312Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record